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Abstract
Background: Polymorphism in the neuropeptide S receptor gene NPSR1 is associated with asthma and inflammatory bowel
disease. NPSR1 is expressed in the brain, where it modulates anxiety and responses to stress, but also in other tissues and
cell types including lymphocytes, the lungs, and the intestine, where it appears to be up-regulated in inflammation. We
sought to determine whether genetic variability at the NPSR1 locus influences the susceptibility and clinical manifestation of
rheumatoid arthritis (RA).
Methodology/Principal Findings: From the Epidemiological Investigation of Rheumatoid Arthritis (EIRA) case-control study,
1,888 rheumatoid arthritis patients and 888 controls were genotyped for 19 single-nucleotide polymorphisms (SNPs)
spanning the entire NPSR1 gene and 220 KB of DNA on chromosome 7p14. The association between individual genetic
markers and their haplotypic combinations, respectively, and diagnosis of RA, presence of autoantibodies to citrullinated
proteins (ACPA), and disease activity score based on 28 joints (DAS28) was tested. There was no association between
diagnosis of RA and NPSR1 variants. However, several associations of nominal significance were detected concerning
susceptibility to ACPA-negative RA and disease activity measures (DAS28). Among these, the association of SNP rs324987
with ACPA-negative RA [(p=0.004, OR=0.674 (95% CI 0.512–0.888)] and that of SNP rs10263447 with DAS28 [p=0.0002,
OR=0.380 (95% CI 0.227–0.635)] remained significant after correction for multiple comparisons.
Conclusions/Significance: NPSR1 polymorphism may be relevant to RA susceptibility and its clinical manifestation. Specific
alleles at the NPSR1 locus may represent common risk factors for chronic inflammatory diseases, including RA.
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Introduction
Rheumatoid arthritis (RA, OMIM 180300) is a complex disease
with a broad spectrum of clinical manifestations, which presents
with joint malfunction and pain, and general inflammatory
symptoms in genetically predisposed individuals. Diagnosis is
based on clinical consensus defined as the American College of
Rheumatology (ACR) criteria.[1] Autoimmunity plays a key role
in the development of RA, and recent progress in defining RA-
specific autoantibodies has pointed to the involvement of different
immunological pathways in this process, including B, T and
macrophage cell functions. Remarkably, it has become evident
that presence of autoantibodies to citrullinated proteins (ACPA)
distinguishes two clinically relevant subgroups of RA: ACPA-
positive and ACPA-negative. Although a differentiation between
these two entities is not currently amenable on biological ground,
it seems that ACPA-negative RA generally represents a milder
disease with lower baseline activity, fewer erosions and better
response to therapy. The heritability of RA was estimated from
twin’s studies between 40 and 77%.[2] Recently, significant
progress has been made in our understanding of the genetic
predisposition to RA, thanks to the implementation of genome-
wide association (GWA) studies and intensive international
collaboration. Together with a confirmation of the importance
of HLA-DRB1 shared epitope alleles and PTPN22 gene variation,
several other susceptibility loci were identified, and convincingly
replicated in different Caucasian populations, including TRAF1-
C5, OLIG3-TNFAIP3, CD40, CCL21 and others.[3–6] While these
results were obtained in RA cohorts mainly represented by ACPA-
positive cases, fewer studies have reported genetic associations in
ACPA-negative RA, namely with HLA-DRB1, IRF5 and DCIR
genes.[7–9] Overall, evidence is emerging of the existence of
different genetic backgrounds and immune-response pathways
contributing to the development of RA in ACPA-positive and
ACPA-negative patients [10].
The neuropeptide S receptor gene (NPSR1), codes for a 7-
transmembrane G protein-coupled receptor (GPCR) of poorly
characterized function. Together with its ligand neuropeptide S
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appears to play a role in stress, anxiety, and in the regulation of
food intake.[11] However, NPSR1 expression is increased during
inflammation in several tissues, and recent work suggests that
NPS-NPSR1 signalling might be involved in the modulation of
immune responses.[12–14] Genetic variation at this locus has been
associated in different populations to asthma (OMIM 600807) and
related traits and, more recently, also to inflammatory bowel
disease (IBD, OMIM 266600).[13,14] It has therefore been
suggested that specific alleles at this locus might act as common
genetic risk factors for the development of chronic inflammatory
diseases. Here, using a candidate gene approach, we sought to
determine whether genetic variation at the NPSR1 locus influences
individual predisposition to rheumatoid arthritis. For this purpose,
19 single nucleotide polymorphisms (SNPs), spanning the entire
220 kb region of the NPSR1 gene, were selected based on reported
associations and/or their tagging properties, and genotyped in
1808 RA cases and 888 healthy controls from the Epidemiological
Investigation of Rheumatoid Arthritis (EIRA) study.
Materials and Methods
Study Population
The Epidemiological Investigation of Rheumatoid Arthritis
(EIRA) is a population-based case-control study, which has been
previously described by us.[15] EIRA cases are defined as
individuals who received a new diagnosis of RA by their
rheumatologist (in 85% of the cases within one year after first
symptoms) and fulfilled the 1987 American College of Rheuma-
tology (ACR) criteria for the classification of RA. ACPA status and
disease activity score based on 28 joints (DAS28) were established
at inclusion in the study, i.e. at first encounter with rheumatology
specialist care, before any immunosuppressive therapy was
initiated. EIRA controls are subjects randomly selected from the
Swedish national population registry, and matched to cases based
on subject’s age, sex, and residential area. The ethics committee of
Karolinska Institutet approved the study. For the purpose of this
investigation, 1808 cases (1332 females, 476 males) and 888
controls (663 females, 225 males), .97% white Caucasians of
Swedish origin, were included in the analyses. Data on ACPA and
DAS28 at baseline were available, respectively, for 1308 (72.3%)
and 629 (34.8%) of the patients included in this study.
Ethics Statement
Verbal consent was received from all patients and it was
registered at clinical journals according to Swedish law. Written
consent was received from healthy control individuals. The ethics
committee of Karolinska Institutet approved the study.
Genotyping
Nineteen NPSR1 SNPs were selected based on their reported
associations with disease(s) and/or tagging properties (with Tagger
software, http://www.broadinstitute.org/mpg/tagger/), and ge-
notyped on genomic DNA using matrix-assisted laser desorption/
ionization time-of-flight (MALDI-TOF) mass spectrometry and
the iPLEX chemistry (SEQUENOM Inc.). Hardy-Weinberg
Equilibrium (HWE) calculations were performed to verify that
each marker was within allelic equilibrium in controls (cut-off p
value=0.05).
Statistical Analysis
Statistical power was estimated using the package ‘‘genetics
1.2.1’’ from R (www.r-project.org). Data were simulated under a
general multiplicative model with Risk Ratio between 1.05 and
2.00 and disease allele frequencies between 0.1 and 0.9. Disease
penetrance was fixed to 50/1000000. SNP disease associations
were tested with a logistic regression using a general additive
model. More specific models (recessive/dominant/genotype) were
applied to the SNPs showing association under the allelic model
with significance lower than the nominal p=0.05. Odds ratios
(OR) were obtained by the model parameters and p values by a
Wald test. Sex was inserted in the model as a covariate. To take
into account multiple testing, the nominal significance threshold of
p=0.05 was corrected by finding the number of independent
SNPs using Principal Component Analysis of the SNPs correlation
matrix. Out of the 19 markers genotyped in this study, 11 resulted
to be statistically independent, which fixed the significance
threshold to p=0.0045 after Bonferroni correction. Haplotypes
were tested using ‘‘haplo.stats 1.3.0’’ from R. Here, haplotype
inference is performed with a standard Expectation Maximization
method and the association is tested with a Generalized Linear
Model, which uses haplotypes posterior probabilities as weights.
Haplotypes were tested over blocks of consecutive markers
as defined in Haploview 4.1 (http://www.broad.mit.edu/mpg/
haploview).
Results
Nineteen SNPs (dbSNPs rs2530543, rs1023556, rs10274146,
rs13246143, rs10259175, rs323917, rs323922, rs1419791,
rs324377, rs324389, rs324398, rs324396, rs324966, rs740347,
rs324981, rs324987, rs10263447, rs6972158, and rs6958905),
spanning approximately 200 kb of Chromosome 7p and including
the entire NPSR1 coding region, were genotyped on 2696
individuals from the EIRA study. The average success rate was
96.5%, and no SNP deviated from expected HWE. As shown in
Figure 1, based on a Haploview 4.1 analysis of genotype data,
these SNPs gave rise to linkage disequilibrium (LD) structure and
minor allele frequencies (MAF) similar to those reported for other
populations of European origin previously studied in asthma and
IBD.[13,14]
To test the potential contribution of the NPSR1 locus to
rheumatoid arthritis, we initially compared the allelic frequencies
of each genotyped SNP in EIRA cases (n=1808) and controls
(n=888). This analysis did not reveal any significant association
(not shown). When available data on anti-citrullinated peptides
antibodies were taken into account, however, sub-grouping of RA
patients into ACPA-positive (n=797) and ACPA-negative
(n=511) individuals provided evidence of an association regarding
ACPA-negative RA for three markers, namely SNPs rs324389
[p=0.008, OR=0.802 (95% CI 0.681–0.944)], rs324981
[p=0.026, OR=0.837 (95% CI 0.716–0.979)] and rs324987
[p=0.041, OR=0.848 (95% CI 0.724–0.993)] (Table 1). In
particular, the two latter SNPs appeared to exert a stronger
predisposing effect under a recessive model, which withstood
Bonferroni correction for multiple testing for rs324987
[p=0.0044, OR=0.674 (95% CI 0.512–0.888)].
We then sought to determine whether NPSR1 polymorphisms
have a disease-modifying effect, by correlating individuals’
genotypes with RA disease activity expressed as Disease Activity
Score in 28 joints (DAS28) in 629 patients, for whom this
information was available. As reported in Table 2, a number of
SNPs showed association of nominal significance with the DAS28
score. Among these, the association of the SNP rs10263447
remained significant after Bonferroni correction when a dominant
model was tested on the entire sample [p=0.0002, OR=0.380
(95% CI 0.227–0.635)], and was observed both in ACPA-positive
[n=393, p=0.005, OR=0.378 (95% CI 0.194–0.739)]) and
NPSR1 and RA
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0.176–0.946)]). No other associations were detected either with
single markers or when NPSR1 haplotypes were inferred from
individual SNP genotypes, in RA as a whole or when patients were
subdivided into phenotypic groups as described above (not shown).
Finally, inclusion of gender as a covariate in the statistical analysis
did not affect the genetic effect estimates of the observed
associations, with the exception of marker rs2530543 that, in
these test, resulted associated (withstanding Bonferroni correction)
with DAS28 only in male patients [n=164, recessive p=0.0041,
OR=0.275 (95% CI 0.115–0.655)].
Discussion
Using a candidate gene approach, we tested here for the first
time the NPSR1 gene for association with rheumatoid arthritis, and
genotyped 19 NPSR1 SNPs in a large cohort of 1808 RA patients
and 888 controls from Sweden. We detected several associations of
nominal significance, both regarding ACPA-negative RA and
when NPSR1 genotypes were correlated with disease activity
expressed as DAS28 scores. In particular, the associations between
SNP rs324987 and ACPA-negative RA (p=0.0044), and SNP
rs10263447 and DAS28 (p=0.0002) remained significant after
correction for the multiple tests performed.
In contrast to the case for ACPA-positive RA, very few genes
have been previously identified that appear to predispose to
ACPA-negative arthritis and, as mentioned, this may reflect the
existence of a predisposing genetic background different from, or
only partially overlapping with, the ACPA-positive form of RA.
ACPA-negative RA is generally characterized by a less severe
phenotype, and our observation that NSPR1 also associates with
DAS28 score is intriguing. It is in fact tempting to speculate that
genetic variability at the NPSR1 locus has indeed an overall impact
on RA susceptibility by affecting the inflammatory process leading
to the establishment and clinical manifestation of this condition.
Of note, recent work suggests that NPS-NPSR1 signalling might be
involved in the modulation of inflammatory and anti-bacterial
responses in T cells and macrophages.[12] NPS stimulation of
epithelial cells stably transfected with NPSR1 results in the
induction of expression, among others, of the neuropeptide
substance P (SP), the pro-inflammatory cytokine interleukin 8
(IL8), and the interleukin 6 receptor (IL6R), together with the
Figure 1. LD map and characteristics of the studied NPSR1 SNPs. Left: LD and haplotype block structure obtained by Haploview 4 analysis of
genotyping data from the EIRA population. The numbers in each box correspond to R-square values between SNPs. Right: SNPs are listed based on
their relative distance in bp and their position in both the NPSR1 gene and its corresponding mRNA).
doi:10.1371/journal.pone.0009315.g001
NPSR1 and RA
PLoS ONE | www.plosone.org 3 February 2010 | Volume 5 | Issue 2 | e9315alpha subunit common to the 4 pituitary gland hormones
chorionic gonadotropin (CG), luteinizing hormone (LH), follicle
stimulating hormone (FSH) and thyroid stimulating hormone
(TSH).[16] Hence, similar to other neuropeptides and their
receptors, NPSR1 appears to play a dual role along the
hypothalamic-pituitary-adrenal (HPA) axis and in inflammation,
and polymorphisms affecting its expression or function might thus
perturb physiological responses ultimately leading to chronic
inflammation and RA.
NPSR1 causative polymorphisms have not yet been conclu-
sively identified and, although association with disease(s) has been
replicated in different populations, there has not been always
complete overlap of markers in previous associations with asthma
and IBD. How genetic variability at this locus can influence
disease predisposition is therefore still poorly understood. The
NPSR1 gene extends for 220 kb of genomic DNA on chromo-
some 7p14, and more than 1400 SNPs mapping within this
region have been identified through sequencing of individuals of
different ethnicity. The SNPs analyzed in this study have been
selected based on previous associations and tagging properties,
and are mostly contained within NPSR1 intronic sequences. In
particular, while an association signal of nominal significance is
observed for several markers spread over half of the gene (110 kb
from intron 2 through exon 9), best statistical evidence
withstanding correction for multiple tests was obtained for SNPs
rs324987 and rs10263447. These two SNPs were not tested in
asthma or IBD in previous studies, where association signals
came mainly from a marker haplotype in intron 2,[13,14], and
map respectively in NPSR1 introns 3 and 4 (Figure 1). They may
thus not impact on the functional properties of the receptor, and
either relate to intragenic regulatory elements or represent LD
proxies for other causative polymorphisms. Interestingly, the SNP
rs324987 that associates with ACPA-negative RA in this study is
in strong LD (r
2=0.99) with the marker rs324981. The latter
corresponds to a coding polymorphism (Asn107Ile) that affects
NPSR1 expression and NPS efficacy,[17,18] and which has been
linked to airway hyperresponsivenes in Chinese asthmatics.[19]
However, this SNP only shows association of nominal significance
with ACPA-negative RA in our study. Hence, although a
predisposing role cannot be excluded until all associated SNPs
have been functionally tested, true risk variants may need to be
sought through an extended and comprehensive analysis of the
NPSR1 locus, both at the genetic and functional level. Ideally, this
may be accomplished also taking into account sex differences in
NPSR1 signalling, since gender-specific effects on disease
associations have been observed, though no information is
available on the potential effect of hormones on receptor function
and/or expression.
In summary, we have provided here initial evidence that NPSR1
SNPs associate with ACPA-negative RA and disease activity.
While key causative polymorphisms await definitive identification
through replication studies and functional characterization, this
and previous findings strongly suggest that NPSR1 genetic variants
may represent common risk factors for chronic inflammatory
conditions such as RA, asthma and IBD. NPSR1 holds the
potential to be exploited as a pharmacological target when
sufficient information on its function(s) is available, and future
studies on this receptor may thus ultimately be of relevance to the
development of novel therapeutic strategies for the treatment of
these common diseases.
Table 1. Association between NPSR1 SNPs and rheumatoid arthritis in ACPA-negative patients vs controls.
MAF
1 statistics
Marker
# Controls Cases pu OR (95% CI) best model
rs2530543 (T/c) 0.183 0.191 0.581 1.058 (0.867–1.292)
rs1023556 (C/t) 0.214 0.221 0.676 1.040 (0.865–1.251)
rs10274146 (A/g) 0.224 0.217 0.689 0.961 (0.791–1.168)
rs13246143 (T/c) 0.214 0.209 0.744 0.969 (0.803–1.170)
rs10259175 (A/g) 0.365 0.352 0.491 0.944 (0.802–1.111)
rs323917(C/g) 0.069 0.059 0.276 0.840 (0.612–1.153)
rs323922 (G/c) 0.433 0.412 0.279 0.918 (0.785–1.072)
rs1419791 (G/a) 0.444 0.430 0.511 0.950 (0.816–1.106)
rs324377 (C/a) 0.460 0.443 0.388 0.934 (0.800–1.090)
rs324389 (C/t) 0.390 0.340 0.008 0.802 (0.681–0.944) allelic (p 0.008)
rs324398 (C/g) 0.309 0.338 0.120 1.137 (0.967–1.337)
rs324396 (C/t) 0.305 0.332 0.135 1.133 (0.962–1.333)
rs324966 (G/a) 0.309 0.303 0.763 0.975 (0.827–1.150)
rs740347 (G/c) 0.139 0.143 0.770 1.034 (0.827–1.292)
rs324981 (A/t) 0.490 0.446 0.026 0.837 (0.716–0.979) recessive (p 0.006)
rs324987 (T/c) 0.490 0.450 0.041 0.848 (0.724–0.993) recessive (p 0.004*)
rs10263447 (G/c) 0.220 0.193 0.080 0.841 (0.693–1.022)
rs6972158 (A/g) 0.337 0.347 0.586 1.046 (0.890–1.230)
rs6958905 (T/c) 0.339 0.348 0.603 1.044 (0.889–1.225)
#Minor allele in lower case.
1MAF = minor allele frequency.
uMinor allele is the tested allele.
*significant after Bonferroni correction for multiple testing.
doi:10.1371/journal.pone.0009315.t001
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